MedTrace Logo

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

NCT03690947 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-12-28

No results posted yet for this study

Summary

The objective of this study is to evaluate if combination of intravitreal ranibizumab with micropulse laser shows non inferiority compared to intravitreal ranibizumab only in diabetic macular edema.

Conditions

Interventions

DRUG

Intravitreal Ranibizumab

All subjections received 3 initial Ranibizumab injections

PROCEDURE

Micropulse Laser

After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists

DRUG

Intravitreal Ranibizumab as needed

After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization

Sponsors & Collaborators

  • Beijing Hospital

    lead OTHER_GOV

Principal Investigators

  • Xiaobing Yu, M.D. · Beijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-08-31
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03690947 on ClinicalTrials.gov